• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aslan Pharmaceuticals Ltd ADR (NQ: ASLN )

    0.3169 -0.0031 (-0.97%)
    Streaming Delayed Price Updated: 3:57 PM EDT, Jun 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 81,622
    Open 0.3400
    Bid (Size) 0.3158 (3)
    Ask (Size) 0.3179 (2)
    Prev. Close 0.3200
    Today's Range 0.3154 - 0.3580
    52wk Range 0.3100 - 4.190
    Shares Outstanding 402,116,835
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
    Via Benzinga

    Performance

    YTD
    -42.38%
    -42.38%
    1 Month
    -29.77%
    -29.77%
    3 Month
    -51.47%
    -51.47%
    6 Month
    -21.21%
    -21.21%
    1 Year
    -91.59%
    -91.59%

    More News

    Read More
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
    From ASLAN PHARMACEUTICALS LIMITED
    Via GlobeNewswire
    ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference
    From ASLAN PHARMACEUTICALS LIMITED
    Via GlobeNewswire
    ASLN Stock Earnings: ASLAN Pharma Beats EPS for Q1 2024
    Via InvestorPlace
    ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From ASLAN PHARMACEUTICALS LIMITED
    Via GlobeNewswire
    ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
    From ASLAN PHARMACEUTICALS LIMITED
    Via GlobeNewswire
    ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
    From ASLAN PHARMACEUTICALS LIMITED
    Via GlobeNewswire
    ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
    From ASLAN PHARMACEUTICALS LIMITED
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
    From ASLAN PHARMACEUTICALS LIMITED
    Via GlobeNewswire
    ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
    From ASLAN PHARMACEUTICALS LIMITED
    Via GlobeNewswire
    ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
    From ASLAN PHARMACEUTICALS LIMITED
    Via GlobeNewswire
    ASLN Stock Earnings: ASLAN Pharma Misses EPS for Q4 2023
    Via InvestorPlace
    ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    From ASLAN PHARMACEUTICALS LIMITED
    Via GlobeNewswire
    Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
    From ASLAN PHARMACEUTICALS LIMITED
    Via GlobeNewswire
    Week In Review: Under Pressure From US Congress, WuXi AppTec Resigns From BIO
    Via Talk Markets
    ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
    From ASLAN PHARMACEUTICALS LIMITED
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
    From ASLAN PHARMACEUTICALS LIMITED
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
    From ASLAN PHARMACEUTICALS LIMITED
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.